Paclitaxel Nanocrystals for Overcoming Multidrug Resistance in Cancer

Citations Over TimeTop 10% of 2010 papers

Abstract

Here we described a paclitaxel (PTX) nanocrystal formulation using d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) as the sole excipient for overcoming multidrug resistance (MDR), a key challenge in current cancer therapy. To the best of our knowledge, it is the first report on PTX nanocrystals which can reverse MDR. TPGS serves as a surfactant to stabilize the nanocrystals and a P-gp inhibitor to reverse MDR. The size and morphology of the nanocrystals were studied by transmission electron microscopy, and the crystalline structure was determined by powder X-ray diffraction. An in vitro drug release profile showed that the nanocrystals exhibited sustained release kinetics compared to Taxol, which is the clinical paclitaxel formulation. The cytotoxicity and antitumor efficacy in xenograft models were also investigated. It is demonstrated that PTX/TPGS nanocrystals have significant advantages over Taxol in achieving better therapeutic effect in Taxol-resistant cancer cells both in vitro and in vivo, which was also confirmed by apoptosis assays. We envision that further development of this type of nanocrystal will provide a novel strategy for drug delivery and multidrug resistance treatment.

Related Papers

• → A TPGS-incorporating nanoemulsion of paclitaxel circumvents drug resistance in breast cancer(2014)88 cited
• → Pharmacologic Sensitivity of Paclitaxel to Its Delivery Vehicles Drives Distinct Clinical Outcomes of Paclitaxel Formulations(2015)44 cited
• Pharmacokinetics of paclitaxel in a hemodialysis patient with advanced gastric cancer： A case report(2006)
• → 1473 POSTER Tocosol® paclitaxel and cremophorel®-paclitaxel: the pharmacokinetic comparison shows that a new paclitaxel formulation leads to increased drug exposure(2005)1 cited
• Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients(2006)